Limited noninvasive prenatal testing (NIPT)
Vasistera is a blood-based genetic, prenatal screening test of the pregnant mom that screens for common chromosomal conditions that affect a baby’s health. Vasistera screens for trisomy 21, trisomy 18, and trisomy 13. Fetal sex reporting is optional. Vasistera can be performed as early as nine weeks gestation. Most results will be returned to your doctor within 5-7 calendar days.
Like Panorama®, our company’s market-leading NIPT, Vasistera leverages the unique SNP*-based methodology to analyze cell-free DNA. Unlike Panorama, Vasistera does not report other chromosomal conditions, such as triploidy, sex chromosome abnormalities, or microdeletions such as 22q11.2 deletion syndrome. Given the more limited approach, Vasistera incorporates analysis of fewer sequencing reads and SNPs than Panorama.
Vasistera is a screening test, which means that this test does not make a final diagnosis. A high-risk result means that your pregnancy has a higher chance of having a specific genetic condition. However, you cannot know for sure if your baby has that condition based upon the screening result alone. All medical decisions should be made after discussion with your healthcare provider regarding diagnostic testing during the pregnancy, like chorionic villus sampling (CVS) or amniocentesis, or testing the baby after birth.
*SNP, single nucleotide polymorphism